White House Addresses Post-Dobbs Access to Medication Abortion (Mifepristone) | Practical Law
The White House has issued a memorandum addressing access to mifepristone—a medication abortion drug approved by the Food and Drug Administration (FDA)—in the wake of the Supreme Court's Dobbs decision, which overturned the federal constitutional right to abortion. The memorandum directs the Department of Health and Human Services (HHS) to consider issuing guidance on barriers to accessing mifepristone and recommendations for addressing these barriers.